Alluvi, known as BI 4744, represents a significant advance in weight management therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling results in clinical trials, potentially https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/